Detalhe da pesquisa
1.
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.
Br J Cancer
; 128(5): 783-792, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470974
2.
Markers of endothelial glycocalyx dysfunction in Clarkson disease.
J Transl Med
; 20(1): 380, 2022 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36038904
3.
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
Breast Cancer Res Treat
; 183(3): 617-627, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32696319
4.
A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis.
J Am Acad Dermatol
; 83(6): 1807-1809, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32289388
5.
Profound impairment of adaptive immune responses by alkylating chemotherapy.
J Immunol
; 190(12): 6259-68, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23686484
6.
Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease.
J Clin Invest
; 134(10)2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502192
7.
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
J Immunother Precis Oncol
; 7(1): 1-6, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38327758
8.
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.
Transplantation
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771067
9.
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
J Pharmacol Exp Ther
; 344(3): 655-64, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23249624
10.
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Invest New Drugs
; 31(4): 1001-7, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23329066
11.
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Lancet Oncol
; 13(5): 539-48, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22452895
12.
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299.
JTO Clin Res Rep
; 4(12): 100584, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38046376
13.
Convolutional Neural Networks for Segmentation of Malignant Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance).
ArXiv
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38076518
14.
The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
Melanoma Res
; 33(6): 514-524, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738028
15.
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas.
Neurooncol Adv
; 5(1): vdad087, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37554223
16.
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Front Immunol
; 14: 1279387, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38022659
17.
Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors.
Onkologie
; 35(4): 210-4, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22488093
18.
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Clin Cancer Res
; 28(12): 2517-2526, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302585
19.
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Thorac Cancer
; 13(21): 3032-3041, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36101520
20.
PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis.
Invest New Drugs
; 29(1): 33-40, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19795097